BioAge Labs, a clinical-stage biotech company focused on therapies for metabolic diseases and aging, announced its participation in two major investor conferences in June 2026. CFO Dr. Dov Goldstein and Chief Strategy Officer Dr. BJ Sullivan will present at the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs Global Healthcare Conference on June 8. They will discuss the company's lead drug candidate BGE-102, which targets cardiovascular and retinal diseases, with Phase 2 data expected by the end of 2026. Webcasts of the presentations will be available for 30 days on BioAge's investor website.
India's military Electro-Optical/Infrared (EO/IR) market is projected to grow to $1.78 billion by 2030 at an 8.9% CAGR, fueled by rising geopolitical tensions and increased border surveillance needs. The market growth is supported by AI integration, ...
Infineon Technologies has partnered with NVIDIA to support the MGX AI Factory ecosystem, focusing on transforming power delivery for advanced AI data centers. Infineon's power management solutions will enable efficient power conversion within NVIDIA'...
Mission Produce has finalized its acquisition of Calavo Growers, creating a stronger, vertically integrated fresh produce company with an expanded footprint in North America. This merger combines two leading avocado providers, enhancing sourcing, pac...
Despite Bitcoin's price falling to around $73,000 and a nearly 48% drop in retail trading volumes in South Korea, major financial groups like Hana Bank, Samsung affiliates, and Hanwha Investment are acquiring significant stakes in local crypto exchan...
The US and Iran have drafted a memorandum outlining a 30-to-60-day ceasefire and negotiations on sanctions, nuclear oversight, and reopening the Strait of Hormuz, a key oil route. Iran promises to restore shipping traffic through the Strait within 30...
